Literature DB >> 27623397

Impact of Alzheimer's Disease, Lewy Body and Vascular Co-Pathologies on Clinical Transition to Dementia in a National Autopsy Cohort.

Jagan A Pillai1, Robert S Butler, Aaron Bonner-Jackson, James B Leverenz.   

Abstract

AIMS: We examined the effect of vascular or Lewy body co-pathologies in subjects with autopsy-confirmed Alzheimer's disease (AD) on the rate of cognitive and functional decline and transition to dementia.
METHODS: In an autopsy sample of prospectively characterized subjects from the National Alzheimer's Coordinating Center database, neuropathology diagnosis was used to define the groups of pure AD (pAD, n = 84), mixed vascular and AD (ADV, n = 54), and mixed Lewy body disease and AD (ADLBD, n = 31). Subjects had an initial Clinical Dementia Rating-Global (CDR-G) score <1, Mini-Mental State Examination ≥15, a final visit CDR-G >1, ≥3 evaluations, and Braak tangle stage ≥III. We compared the rate of cognitive and functional decline between the groups.
RESULTS: The rate of functional and cognitive decline was lower for ADV, and ADV patients had less severe deficits on CDR-G and the CDR-Sum of Boxes scores at the last visit than pAD and ADLBD patients. No significant differences were noted between ADLBD and pAD patients. After controlling for age at death, the odds of reaching CDR ≥1 at the last visit were lower in the ADV subjects compared to the pAD subjects.
CONCLUSIONS: The mean rate of functional and cognitive decline among ADV subjects was slower than among either pAD or ADLBD patients. Vascular pathology did not increase the odds of attaining CDR ≥1 when occurring with AD in this national cohort.
© 2016 S. Karger AG, Basel.

Entities:  

Mesh:

Year:  2016        PMID: 27623397      PMCID: PMC5451902          DOI: 10.1159/000448243

Source DB:  PubMed          Journal:  Dement Geriatr Cogn Disord        ISSN: 1420-8008            Impact factor:   2.959


  31 in total

1.  Relative frequencies of Alzheimer disease, Lewy body, vascular and frontotemporal dementia, and hippocampal sclerosis in the State of Florida Brain Bank.

Authors:  Warren W Barker; Cheryl A Luis; Alice Kashuba; Mercy Luis; Dylan G Harwood; David Loewenstein; Carol Waters; Pat Jimison; Eugene Shepherd; Steven Sevush; Neil Graff-Radford; Douglas Newland; Murray Todd; Bayard Miller; Michael Gold; Kenneth Heilman; Leilani Doty; Ira Goodman; Bruce Robinson; Gary Pearl; Dennis Dickson; Ranjan Duara
Journal:  Alzheimer Dis Assoc Disord       Date:  2002 Oct-Dec       Impact factor: 2.703

2.  Cerebrovascular pathology and dementia in autopsied Honolulu-Asia Aging Study participants.

Authors:  Lon White; Helen Petrovitch; John Hardman; James Nelson; Daron G Davis; G Webster Ross; Kamal Masaki; Lenore Launer; William R Markesbery
Journal:  Ann N Y Acad Sci       Date:  2002-11       Impact factor: 5.691

3.  Vascular burden and Alzheimer disease pathologic progression.

Authors:  Raymond Y Lo; William J Jagust
Journal:  Neurology       Date:  2012-09-12       Impact factor: 9.910

4.  Silent brain infarcts and the risk of dementia and cognitive decline.

Authors:  Sarah E Vermeer; Niels D Prins; Tom den Heijer; Albert Hofman; Peter J Koudstaal; Monique M B Breteler
Journal:  N Engl J Med       Date:  2003-03-27       Impact factor: 91.245

5.  Cognitive differences in dementia patients with autopsy-verified AD, Lewy body pathology, or both.

Authors:  M L Kraybill; E B Larson; D W Tsuang; L Teri; W C McCormick; J D Bowen; W A Kukull; J B Leverenz; M M Cherrier
Journal:  Neurology       Date:  2005-06-28       Impact factor: 9.910

6.  Cognitive decline is faster in Lewy body variant than in Alzheimer's disease.

Authors:  J M Olichney; D Galasko; D P Salmon; C R Hofstetter; L A Hansen; R Katzman; L J Thal
Journal:  Neurology       Date:  1998-08       Impact factor: 9.910

7.  Cerebral infarctions and the likelihood of dementia from Alzheimer disease pathology.

Authors:  J A Schneider; R S Wilson; J L Bienias; D A Evans; D A Bennett
Journal:  Neurology       Date:  2004-04-13       Impact factor: 9.910

Review 8.  The Alzheimer's Disease Centers' Uniform Data Set (UDS): the neuropsychologic test battery.

Authors:  Sandra Weintraub; David Salmon; Nathaniel Mercaldo; Steven Ferris; Neill R Graff-Radford; Helena Chui; Jeffrey Cummings; Charles DeCarli; Norman L Foster; Douglas Galasko; Elaine Peskind; Woodrow Dietrich; Duane L Beekly; Walter A Kukull; John C Morris
Journal:  Alzheimer Dis Assoc Disord       Date:  2009 Apr-Jun       Impact factor: 2.703

9.  Vascular and amyloid pathologies are independent predictors of cognitive decline in normal elderly.

Authors:  Prashanthi Vemuri; Timothy G Lesnick; Scott A Przybelski; David S Knopman; Greg M Preboske; Kejal Kantarci; Mekala R Raman; Mary M Machulda; Michelle M Mielke; Val J Lowe; Matthew L Senjem; Jeffrey L Gunter; Walter A Rocca; Rosebud O Roberts; Ronald C Petersen; Clifford R Jack
Journal:  Brain       Date:  2015-01-15       Impact factor: 13.501

10.  Prevalence of mixed pathologies in the aging brain.

Authors:  Jasmin Rahimi; Gabor G Kovacs
Journal:  Alzheimers Res Ther       Date:  2014-11-21       Impact factor: 6.982

View more
  8 in total

1.  Cognitive tests aid in clinical differentiation of Alzheimer's disease versus Alzheimer's disease with Lewy body disease: Evidence from a pathological study.

Authors:  Martina Azar; Silvia Chapman; Yian Gu; James B Leverenz; Yaakov Stern; Stephanie Cosentino
Journal:  Alzheimers Dement       Date:  2020-06-19       Impact factor: 21.566

2.  Impact of the Presence of Select Cardiovascular Risk Factors on Cognitive Changes among Dementia Subtypes.

Authors:  Katherine E Irimata; Brittany N Dugger; Jeffrey R Wilson
Journal:  Curr Alzheimer Res       Date:  2018       Impact factor: 3.498

3.  Mixed neuropathologies and associations with domain-specific cognitive decline.

Authors:  Willa D Brenowitz; Rebecca A Hubbard; C Dirk Keene; Stephen E Hawes; W T Longstreth; Randy L Woltjer; Walter A Kukull
Journal:  Neurology       Date:  2017-09-22       Impact factor: 9.910

Review 4.  Neuroscience learning from longitudinal cohort studies of Alzheimer's disease: Lessons for disease-modifying drug programs and an introduction to the Center for Neurodegeneration and Translational Neuroscience.

Authors:  Justin B Miller; Jeffrey Cummings; Christin Nance; Aaron Ritter
Journal:  Alzheimers Dement (N Y)       Date:  2018-07-11

5.  Temporal Ordering of Inflammatory Analytes sTNFR2 and sTREM2 in Relation to Alzheimer's Disease Biomarkers and Clinical Outcomes.

Authors:  Jagan A Pillai; Maria Khrestian; James Bena; James B Leverenz; Lynn M Bekris
Journal:  Front Aging Neurosci       Date:  2021-06-29       Impact factor: 5.750

6.  Clinical Profiles of Arteriolosclerosis and Alzheimer Disease at Mild Cognitive Impairment and Mild Dementia in a National Neuropathology Cohort.

Authors:  Dixon Yang; Arjun V Masurkar
Journal:  Alzheimer Dis Assoc Disord       Date:  2021 Jan-Mar 01       Impact factor: 2.357

7.  Spatial patterns of correlation between cortical amyloid and cortical thickness in a tertiary clinical population with memory deficit.

Authors:  Jagan A Pillai; Mykol Larvie; Jacqueline Chen; Anna Crawford; Jeffery L Cummings; Stephen E Jones
Journal:  Sci Rep       Date:  2020-11-26       Impact factor: 4.379

8.  Heterogeneity of cellular inflammatory responses in ageing white matter and relationship to Alzheimer's and small vessel disease pathologies.

Authors:  Rachel Waller; Ruth Narramore; Julie E Simpson; Paul R Heath; Nikita Verma; Megan Tinsley; Jordan R Barnes; Hanna T Haris; Frances E Henderson; Fiona E Matthews; Connor D Richardson; Carol Brayne; Paul G Ince; Raj N Kalaria; Stephen B Wharton
Journal:  Brain Pathol       Date:  2021-02-15       Impact factor: 7.611

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.